证券代码：002688 证券简称：金河生物 公告编号：2025-065 金河生物科技股份有限公司 关于 2023 年限制性股票激励计划首次授予第二个 解除限售期解除限售股份上市流通的提示性公告 （一）本次首次授予第二个解除限售期符合解除限售资格的激励对象 70 名， 可解除限售的限制性股票 4,326,000 股。 （二）金河生物科技股份有 限公司（以下简称"公司"）目前股本为 （三）本次解除限售的限制性股票限售起始日期为 2023 年 7 月 7 日，承诺 的限售期限为 24 个月，上市流通日为 2025 年 7 月 21 日。 公司于 2025 年 7 月 7 日分别召开第六届董事会第二十七次会议和第六届监 事会第二十二次会议，审议通过《关于 2023 年限制性股票激励计划首次授予第 二个解除限售期及预留授予第一个解除限售期解除限售条件成就的议案》。鉴于 限售期的解除限售条件已成就，根据公司 2022 年度股东大会对董事会的授权， 公司按规定为首次授予第二个解除限售期符合解除限售资格的激励对象 70 名办 理限制性股票解除限售股份上市流通的相关事宜。本次可解除限售的限制性股票 一、本激励计划已履行的相关审 ...

证券代码：002688 证券简称：金河生物 公告编号：2025-065 金河生物科技股份有限公司 关于 2023 年限制性股票激励计划首次授予第二个 解除限售期解除限售股份上市流通的提示性公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 重要内容提示： （一）本次首次授予第二个解除限售期符合解除限售资格的激励对象 70 名， 可解除限售的限制性股票 4,326,000 股。 （二）金河生物科技股份有限公司（以下简称"公司"）目前股本为 771,634,398 股，本次首次授予第二个解除限售期可解除限售的限制性股票 4,326,000 股，占公司目前总股本的 0.5606%。 （三）本次解除限售的限制性股票限售起始日期为 2023 年 7 月 7 日，承诺 的限售期限为 24 个月，上市流通日为 2025 年 7 月 21 日。 公司于 2025 年 7 月 7 日分别召开第六届董事会第二十七次会议和第六届监 事会第二十二次会议，审议通过《关于 2023 年限制性股票激励计划首次授予第 二个解除限售期及预留授予第一个解除限售期解除限售条件成就的议 ...

金河生物科技股份有限公司（以下简称"公司"）于2025年4月18日及2025 年5月6日分别召开了第六届董事会第二十四次会议和2025年第二次临时股东大 会，审议并通过了《关于变更公司注册资本及修订<公司章程>部分条款的议案》。 具 体 内 容 详 见 公 司 于 2025 年 4 月 19 日 、 2025 年 5 月 7 日 于 巨 潮 资 讯 网 （http://www.cninfo.com.cn）披露的相关公告。 公司于2025年6月10日及2025年6月26日分别召开了第六届董事会第二十六 次会议和2025年第三次临时股东大会，审议并通过了《关于增加公司经营范围并 修改<公司章程>的议案》。具体内容详见公司于2025年6月11日、2025年6月27 日于巨潮资讯网（http://www.cninfo.com.cn）披露的相关公告。 证券代码：002688 证券简称：金河生物 公告编号：2025-064 金河生物科技股份有限公司 关于完成工商变更登记的公告 公司于近日完成了工商变更登记及备案手续，并取得了呼和浩特市行政审批 和政务服务局颁发的《营业执照》，现将具体信息公告如下： 统一社会信用代码：91 ...

Group 1 - The company expects a positive net profit for the first half of 2025, indicating an upward trend in performance [1][2] - The performance forecast period is from January 1, 2025, to June 30, 2025 [1] - The company has not yet audited the performance forecast by a registered accounting firm [1] Group 2 - The sales of the veterinary chemical drug segment have been strong, with increased sales of the main product, oxytetracycline, in both domestic and overseas markets [2] - The completion of the company's sixth-phase project has led to increased production capacity, meeting market demand and generating more profit [2] - The agricultural product processing segment has benefited from a decline in corn prices, contributing positively to overall performance [2]

Core Viewpoint - The article summarizes significant announcements from various listed companies in the Shanghai and Shenzhen stock markets, highlighting changes in control, major asset acquisitions, and performance forecasts for the first half of 2025. Group 1: Control Changes and Stock Suspension - Yangdian Technology is planning a change in control, leading to a stock suspension starting July 14, 2025, for up to 2 trading days [3] - Yuanli Co. is also planning to acquire control of Fujian Tongsheng New Materials Technology, resulting in a stock suspension starting July 14, 2025, for up to 10 trading days [5] - Kanghua Bio is planning a change in control, with stock suspension starting July 14, 2025, for up to 2 trading days [6] - Fuda Alloy is planning to acquire at least 51% of Guangda Electronics, which constitutes a major asset restructuring but will not change the actual controller [7] Group 2: Performance Forecasts - Limin Co. expects a net profit of 260 million to 280 million yuan for H1 2025, a year-on-year increase of 719.25% to 782.27% due to rising sales and prices [9] - Zijin Mining anticipates a net profit of approximately 23.2 billion yuan for H1 2025, a year-on-year increase of about 54% [10] - Chunqiu Electronics forecasts a net profit of 90 million to 110 million yuan for H1 2025, an increase of 236.05% to 310.72% [11] - Jinqilin expects a net profit of around 106 million yuan for H1 2025, a year-on-year increase of 222.36% [12] - Beihua Co. anticipates a net profit of 98 million to 111 million yuan for H1 2025, a year-on-year increase of 182.72% to 220.23% [14] - Guojin Securities expects a net profit of 1.092 billion to 1.137 billion yuan for H1 2025, a year-on-year increase of 140% to 150% [15] - Jiu Yuan Silver Sea forecasts a net profit of 26.49 million to 32.25 million yuan for H1 2025, a year-on-year increase of 130% to 180% [16] - Lankai Technology expects a net profit of 1.1 billion to 1.2 billion yuan for H1 2025, a year-on-year increase of 85.5% to 102.36% [17] - Changcheng Securities anticipates a net profit of 1.335 billion to 1.407 billion yuan for H1 2025, a year-on-year increase of 85% to 95% [18] - Weilan Lithium Core expects a net profit of 300 million to 360 million yuan for H1 2025, a year-on-year increase of 79.29% to 115.15% [19] - Yinlong Co. forecasts a net profit of 161 million to 181 million yuan for H1 2025, a year-on-year increase of 60% to 80% [21] - Aopumai expects a net profit of approximately 37 million yuan for H1 2025, a year-on-year increase of 53.28% [22] - Bailong Dongfang anticipates a net profit of 350 million to 410 million yuan for H1 2025, a year-on-year increase of 50.21% to 75.97% [23] - Shanghai Electric expects a net profit of 1.754 billion to 2.087 billion yuan for H1 2025, a year-on-year increase of 32.18% to 57.27% [24] - Huazhong Securities expects a net profit of 1.035 billion yuan for H1 2025, a year-on-year increase of 44.94% [25] - Bailong Chuangyuan anticipates a net profit of 171 million yuan for H1 2025, a year-on-year increase of 42.68% [26] - Chengyi Pharmaceutical expects a net profit of 107 million to 119 million yuan for H1 2025, a year-on-year increase of 40% to 55% [27] - Jinhai Biological anticipates a net profit of 127 million to 141 million yuan for H1 2025, a year-on-year increase of 40% to 55% [28] - Kanda New Materials expects a net profit of 50 million to 55 million yuan for H1 2025, turning from loss to profit [29] - China Shenhua expects a net profit of 23.6 billion to 25.6 billion yuan for H1 2025, a year-on-year decrease of 8.6% to 15.7% [30] - ST Songfa anticipates a net profit of 580 million to 700 million yuan for H1 2025, turning from loss to profit [31] - Chengxing Co. expects a net profit of 16 million to 23 million yuan for H1 2025, turning from loss to profit [33] - Ningbo Fubon anticipates a net profit of 8 million to 12 million yuan for H1 2025, turning from loss to profit [34] - ST Yundong expects a loss of 100 million to 150 million yuan for H1 2025, worsening from the previous year [35] - Kairuide expects a loss of 15 million to 22 million yuan for H1 2025, turning from profit to loss [36] Group 3: Shareholding Changes - Defu Technology's shareholders plan to reduce their holdings by up to 4.04% [38] - Jinzhen Co.'s shareholders plan to reduce their holdings by up to 3.04% [39] - Shikong Technology's shareholder plans to reduce their holdings by up to 3% [40] - Qilu Bank's shareholder plans to reduce their holdings by up to 1.1% [41] - Zhongci Electronics' shareholder plans to reduce their holdings by up to 1% [42] - Jiamei Packaging's shareholders plan to reduce their holdings by up to 1% [43] - Saike Xide's shareholder plans to reduce their holdings by up to 1% [44] - Gongda High-tech's general manager plans to reduce their holdings by up to 0.3424% [46] - Qingyuan Co.'s shareholder plans to reduce their holdings by up to 273,800 shares [47] Group 4: Major Contracts - Dashijiang expects to win a procurement project worth 122 million yuan [49] - Robotech signed significant daily operational contracts worth approximately 14.18 million USD [50]

Corporate Announcements - Yangdian Technology is planning a change in control, leading to a suspension of its stock from July 14, 2025, for up to 2 trading days [3] - Degute is planning to acquire 100% of Haowei Technology through a combination of share issuance and cash payment, with stock resuming trading on July 14, 2025 [4] - Yuanli Co. is planning to acquire control of Fujian Tongsheng New Materials Technology, resulting in a stock suspension starting July 14, 2025, for up to 10 trading days [5] - Kanghua Bio is also planning a change in control, with stock suspension from July 14, 2025, for up to 2 trading days [6] - Fuda Alloy is planning to acquire at least 51% of Guangda Electronics, which will constitute a major asset restructuring but will not change the actual controller [7] Performance Forecasts - Limin Co. expects a net profit of 260 million to 280 million yuan for the first half of 2025, a year-on-year increase of 719.25% to 782.27% [9] - Zijin Mining anticipates a net profit of approximately 23.2 billion yuan for the first half of 2025, a year-on-year increase of about 54% [10] - Chunqiu Electronics forecasts a net profit of 9 million to 11 million yuan, an increase of 236.05% to 310.72% year-on-year [12] - Jinqilin expects a net profit of approximately 106 million yuan, a year-on-year increase of 222.36% [13] - Beihua Co. anticipates a net profit of 98 million to 111 million yuan, a year-on-year increase of 182.72% to 220.23% [14] - Guojin Securities expects a net profit of 1.092 billion to 1.137 billion yuan, a year-on-year increase of 140% to 150% [15] - Jiuyuan Silver Sea forecasts a net profit of 26.49 million to 32.25 million yuan, a year-on-year increase of 130% to 180% [16] - Lankai Technology expects a net profit of 1.1 billion to 1.2 billion yuan, a year-on-year increase of 85.5% to 102.36% [17] - Changcheng Securities anticipates a net profit of 1.335 billion to 1.407 billion yuan, a year-on-year increase of 85% to 95% [18] - Weilan Lithium Core expects a net profit of 300 million to 360 million yuan, a year-on-year increase of 79.29% to 115.15% [19] - Yinlong Co. forecasts a net profit of 161 million to 181 million yuan, a year-on-year increase of 60% to 80% [20] - Aopumai expects a net profit of approximately 37 million yuan, a year-on-year increase of 53.28% [22] - Bailong Dongfang anticipates a net profit of 350 million to 410 million yuan, a year-on-year increase of 50.21% to 75.97% [23] - Shanghai Electric expects a net profit of 1.754 billion to 2.087 billion yuan, a year-on-year increase of 32.18% to 57.27% [24] - Huazheng Securities reports a net profit of 1.035 billion yuan, a year-on-year increase of 44.94% [25] - Bailong Chuangyuan expects a net profit of 171 million yuan, a year-on-year increase of 42.68% [26] - Chengyi Pharmaceutical anticipates a net profit of 107 million to 119 million yuan, a year-on-year increase of 40% to 55% [27] - Jinhai Biological expects a net profit of 127 million to 141 million yuan, a year-on-year increase of 40% to 55% [28] - Kangda New Materials forecasts a net profit of 50 million to 55 million yuan, turning from loss to profit [29] - China Shenhua expects a net profit of 23.6 billion to 25.6 billion yuan, a year-on-year decrease of 8.6% to 15.7% [30] - ST Songfa anticipates a net profit of 580 million to 700 million yuan, turning from loss to profit [31] - Chengxing Co. expects a net profit of 16 million to 23 million yuan, turning from loss to profit [32] - Bofubang anticipates a net profit of 8 million to 12 million yuan, turning from loss to profit [33] - ST Yundong expects a loss of 100 million to 150 million yuan, an increase in loss compared to the previous year [34] - Kerryde expects a loss of 15 million to 22 million yuan, turning from profit to loss [35] Shareholding Changes - Defu Technology's shareholders plan to reduce their holdings by up to 4.04% [37] - Jinzhen Co.'s shareholders plan to reduce their holdings by up to 3.04% [38] - Shikong Technology's shareholder plans to reduce their holdings by up to 3% [39] - Qilu Bank's shareholder plans to reduce their holdings by up to 1.1% [40] - Zhongci Electronics' shareholder plans to reduce their holdings by up to 1% [41] - Jiamei Packaging's shareholders plan to reduce their holdings by up to 1% [42] - Saike Xide's shareholder plans to reduce their holdings by up to 1% [43] - Gongda High-Tech's general manager plans to reduce their holdings by up to 0.3424% [44] - Qingyuan Co.'s shareholder plans to reduce their holdings by up to 273,800 shares [45] Major Contracts - Dash Intelligent has been pre-awarded a procurement project worth 122 million yuan [46] - Robotech has signed significant daily operational contracts amounting to approximately 1.418 million USD [48]

Core Viewpoint - Jinhe Biology (002688.SZ) expects a net profit increase of 40%-55% for the first half of 2025, projecting a profit range of 127 million to 141 million yuan compared to the same period last year [1] Group 1: Financial Performance - The expected net profit for the first half of 2025 is between 127 million and 141 million yuan, indicating a growth of 40%-55% year-on-year [1] - The growth is attributed to strong sales in the veterinary chemical drug segment, particularly the main product, Chlortetracycline, which saw increased sales in both domestic and overseas markets [1] Group 2: Operational Highlights - The overseas market sales have continued to grow, contributing positively to overall performance [1] - The completion of the sixth phase project has increased production capacity, ensuring supply meets demand and generating additional profits [1] Group 3: Sector Contributions - The agricultural product processing segment benefited from a decline in corn prices, which also contributed to the overall performance improvement [1]

Performance Forecast - The company expects a net profit of 127.43 million to 141.08 million yuan for the period from January 1, 2025, to June 30, 2025, representing a growth of 40% to 55% compared to the same period last year, where the profit was 91.02 million yuan [1] - The net profit after deducting non-recurring gains and losses is expected to be between 117.83 million and 131.48 million yuan, an increase of 38.70% to 54.78% from last year's 84.95 million yuan [1] - Basic earnings per share are projected to be between 0.1651 yuan and 0.1828 yuan, compared to 0.1166 yuan in the previous year [1] Reasons for Performance Change - The sales of the veterinary chemical drug segment have continued to improve, with significant growth in both domestic and international markets, particularly in the overseas market [1] - The completion of the company's sixth-phase project has increased production capacity, ensuring supply for both domestic and international markets, which has contributed to higher profits [1] - The agricultural product processing segment has benefited from a decline in the price of corn, positively impacting overall performance [1]

证券代码：002688 证券简称：金河生物 公告编号:2025-063 金河生物科技股份有限公司 2025 年半年度业绩预告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 | 项 目 | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | | 归属于上市公司股东 | 盈利：12,742.88 | 万元-14,108.19 万元 | 盈利：9,102.06 | 万元 | | 的净利润 | 比上年同期增长 | 40%-55% | | | | 扣除非经常性损益后 归属于上市公司股东 | 盈利：11,782.73 | 万元–13,148.04 万元 | 盈利：8,494.87 | 万元 | | | 比上年同期增长：38.70%-54.78% | | | | | 的净利润 | | | | | | 基本每股收益 | 盈利：0.1651 | 元/股-0.1828 元/股 | 盈利：0.1166 | 元/股 | 二、与会计师事务所沟通情况 公司本次业绩预告未经注册会计师审计。 三、业绩变动原因说明 本报告期，公司兽 ...

Group 1: Project and Investment Updates - The company has not arranged for the construction of the erythritol project and has no related information to provide at this time [1] - The company has completed fundraising but has no specific plans for the erythritol project, nor a timeline for construction [1] - The company is focusing on existing projects and has no further restructuring plans [2] Group 2: Market and Trade Impact - The trade war has not affected the company's export products, and export volumes remain stable [1] - The company has implemented price increases in the U.S. market to cover tariff costs [1] - The company maintains a stable market share globally, despite fluctuations in international trade [1] Group 3: Product Performance and Sales - The company's chemical drug product, Jinmeisu, has maintained a high reputation and stable supply-demand relationship in the market [2] - The main vaccine product, Blue Ear Inactivated Vaccine, continues to hold the number one market share [2] - The company’s new production capacity for chemical drugs is currently at 100% utilization [2] Group 4: Future Development Strategies - The company aims to enhance product quality, innovation capabilities, and market share to ensure steady profit growth [2] - The company is actively pursuing strategic development goals and aims to achieve a market value of 20 billion [3] - The company is exploring new avenues in the animal health sector while focusing on existing product development [2] Group 5: Financial and Operational Insights - The company’s logistics costs for the first half of 2025 are still being compiled, with details to be disclosed in the upcoming half-year report [5] - The company has invested 158 million in a wastewater treatment project to enhance its capabilities and profitability [4] - The company is closely monitoring the impact of corn price fluctuations on product costs and adjusting procurement strategies accordingly [4]